Background
Phase 3, pragmatic, open-label, randomized 1:1, non-inferiority trial in Japan. N=970 (ITT). Refractory metastatic colorectal cancer. Tests simplified biweekly FTD-TPI schedule to reduce myelosuppression while preserving efficacy of SUNLIGHT regimen.
Results
Interventions and follow up: Arm A: 14-day schedule: FTD-TPI 35 mg/m2 PO BID d1–5 + bevacizumab 5 mg/kg d1, q2w (n=484)
Arm B: 28-day schedule: FTD-TPI 35 mg/m2 PO BID d1–5, d8–12 + bevacizumab 5 mg/kg d1, d15, q4w (n=486)
Primary endpoint: OS (non-inferiority)
mFollow up: 17.9 mo
Results: OS: 11.3 vs 10.3 mo; HR 0.93 (95% CI 0.80–1.08); non-inferiority met
OS 12 mo: 47.5% vs 44.0%
Arm B: 28-day schedule: FTD-TPI 35 mg/m2 PO BID d1–5, d8–12 + bevacizumab 5 mg/kg d1, d15, q4w (n=486)
Primary endpoint: OS (non-inferiority)
mFollow up: 17.9 mo
Results: OS: 11.3 vs 10.3 mo; HR 0.93 (95% CI 0.80–1.08); non-inferiority met
OS 12 mo: 47.5% vs 44.0%
Adverse events
Neutropenia G≥3: 13% vs 39% (absolute difference 25 percentage points)
Anorexia G≥2: 15% vs 26%
Treatment-related deaths: 2 vs 0
Anorexia G≥2: 15% vs 26%
Treatment-related deaths: 2 vs 0
Conclusions
Biweekly FTD-TPI + bevacizumab was non-inferior to the standard 28-day schedule for OS while sharply reducing neutropenia and anorexia. Supports the 14-day schedule as a new standard for FTD-TPI + bevacizumab in refractory mCRC.
Key Limitations
Open-label, Japan-only population; Asian patients may differ in FTD-TPI tolerability/pharmacokinetics. Pragmatic design; NI margin and PFS/QoL details beyond abstract to be reviewed. Dose intensity of FTD-TPI per 28 days is halved, so equivalence relies on bevacizumab synergy and schedule; not tested for FTD-TPI monotherapy. Median follow-up 17.9 mo adequate for refractory setting.
Clinical Context
SUNLIGHT established FTD-TPI + bevacizumab (28-day schedule) as standard 3L+ mCRC (FDA-approved 2023; NCCN/ESMO preferred). Prior phase 2 data (e.g., Danish/Japanese biweekly studies) suggested similar efficacy with less toxicity. PRABITAS provides phase 3 evidence for the biweekly schedule; alternative to fruquintinib or regorafenib in later lines. Label schedule unchanged; guideline adoption pending.
